Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma.

Trial Profile

Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs Zoledronic acid (Primary) ; Cisplatin; Dexrazoxane; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2012 Actual end date (1 Apr 2012 ) added as reported by ClinicalTrials.gov.
    • 17 Apr 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top